18F-氟环丁氨酸PET/MR评估去势抵抗性前列腺癌骨转移的表现
本研究纳入8例去势抵抗性前列腺癌骨转移患者,共13次18F-氟环丁氨酸PET/MR检查,比较骨扫描、单独MR、单独PET及PET/MR对骨转移灶的检出性能。结果显示PET/MR与单独MR检出率最高(分别为100%和99%),单独PET对晚期硬化灶检出率较低,病灶SUVmax与ADCmean呈中度负相关。
要点
- 18F-氟环丁氨酸PET/MR与单独MR对CRPC骨转移检出率高,两者差异无统计学意义。
- 单独18F-氟环丁氨酸PET对晚期硬化性骨转移灶检出率较低。
- 病灶SUVmax与ADCmean呈中度负相关,提示肿瘤代谢与细胞密度可能相关。
核心结论
- 18F-氟环丁氨酸PET/MR与单独MR对去势抵抗性前列腺癌骨转移具有高敏感性。
- 单独18F-氟环丁氨酸PET在检测晚期硬化性病灶时表现不佳。
- 病灶SUVmax与ADCmean呈中度负相关,提示肿瘤代谢与细胞密度之间可能存在关系。
研究设计与样本
- 研究纳入8例去势抵抗性前列腺癌骨转移患者,部分在镭治疗前、部分在镭治疗后,共进行13次18F-氟环丁氨酸PET/MR检查。
- 分析比较了放射性核素骨扫描、单独MR、单独18F-氟环丁氨酸PET及18F-氟环丁氨酸PET/MR对骨转移灶的检出性能。
- 参考标准为临床信息结合既往与随访影像的对照。
主要发现
- 13次检查共评估347个转移性骨病灶,单独18F-氟环丁氨酸PET检出238/347(68%)。
- 放射性核素骨扫描检出286/347(82%),单独MR检出344/347(99%),18F-氟环丁氨酸PET/MR检出347/347(100%)。
- 18F-氟环丁氨酸PET/MR与MR表现最佳(p < 0.001),两者之间差异无统计学意义(p = 0.25)。
- 单独18F-氟环丁氨酸PET检出率较低,尤其对晚期硬化性病灶(p < 0.001)。
- 病灶SUVmax与ADCmean呈中度负相关(r = -0.49;p < 0.001)。
关键数值与推荐
- 18F-氟环丁氨酸PET/MR检出全部347个骨转移灶(100%),单独MR检出344/347(99%)。
- 单独18F-氟环丁氨酸PET检出238/347(68%),放射性核素骨扫描检出286/347(82%)。
- PET/MR与MR之间差异无统计学意义(p = 0.25),PET/MR与MR均优于单独PET(p < 0.001)。
- 晚期硬化性病灶中单独18F-氟环丁氨酸PET检出率更低(p < 0.001)。
- 病灶SUVmax与ADCmean相关系数r = -0.49(p < 0.001)。
临床怎么用
- 对于去势抵抗性前列腺癌骨转移评估,18F-氟环丁氨酸PET/MR或单独MR可提供高灵敏检出。
- 单独18F-氟环丁氨酸PET不宜单独用于排除晚期硬化性骨转移灶。
- SUVmax与ADCmean的负相关可用于提示病灶代谢与细胞密度的关系,但需进一步验证。
局限性
- 样本量小,仅纳入8例患者共13次检查。
- 部分患者处于镭治疗前、部分处于镭治疗后,状态不完全一致。
- 参考标准为临床信息结合影像对照,非病理金标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: 18F-Fluciclovine is indicated for evaluation of suspected prostate cancer (PCa) biochemical recurrence. There are few studies investigating fluciclovine with PET/MR and none evaluated osseous metastases. Our aim was to assess the performance of 18F-fluciclovine PET/MR (fluciclovine-PET/MR) for detecting osseous metastases in patients with castration-resistant prostate cancer (CRPC). We also investigated possible correlations between SUVmax and ADCmean. METHODS: We evaluated 8 patients with CRPC metastatic to bones, some before and some after radium therapy, who underwent 13 fluciclovine-PET/MR studies. We analyzed the performance of radionuclide bone scan (RBS), MR alone, fluciclovine-PET alone, and fluciclovine-PET/MR in detecting osseous metastases. Lesion size, characteristics (early sclerotic, late sclerotic, mixed, lytic), SUVmax, and ADCmean were assessed. The reference standard was a combination of clinical information and correlation with both prior and follow-up imaging. RESULTS: Of 347 metastatic bony lesions in 13 studies, 238/347 (68%) were detected by fluciclovine-PET alone, 286/347 (82%) by RBS, 344/347 (99%) by MR alone, and 347/347 (100%) by fluciclovine-PET/MR. Fluciclovine-PET/MR and MR had the best performance (p < 0.001). There was no statistically significant difference between fluciclovine-PET/MR and MR alone (p = 0.25). Fluciclovine-PET had a lower detection rate especially with late sclerotic lesions (p < 0.001). There was a moderate inverse correlation between lesion SUVmax and ADCmean (r = - 0.49; p < 0.001). CONCLUSIONS: This study suggests that fluciclovine-PET/MR and MR have high sensitivity for detecting osseous metastases in CRPC. Fluciclovine-PET alone underperformed in detecting late sclerotic lesions. The inverse correlation between SUVmax and ADCmean suggests a possible relationship between tumor metabolism and cellularity.
引用
- Amorim BJ, Prabhu V, Marco SS, et al. Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019. PMID: 31492992. doi:10.1007/s00259-019-04506-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。